1. Home
  2. SPRO vs RYOJ Comparison

SPRO vs RYOJ Comparison

Compare SPRO & RYOJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SPRO

Spero Therapeutics Inc.

N/A

Current Price

$1.14

Market Cap

71.0M

Sector

Health Care

ML Signal

N/A

Logo rYojbaba Co. Ltd.

RYOJ

rYojbaba Co. Ltd.

N/A

Current Price

$4.00

Market Cap

56.9M

ML Signal

N/A

Company Overview

Basic Information
Metric
SPRO
RYOJ
Founded
2013
2015
Country
United States
Japan
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Professional Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
71.0M
56.9M
IPO Year
2017
2024

Fundamental Metrics

Financial Performance
Metric
SPRO
RYOJ
Price
$1.14
$4.00
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
355.5K
28.2K
Earning Date
05-13-2026
12-15-2025
Dividend Yield
N/A
N/A
EPS Growth
111.81
N/A
EPS
N/A
N/A
Revenue
$66,802,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$300.00
N/A
P/E Ratio
N/A
$19.04
Revenue Growth
39.24
N/A
52 Week Low
$1.08
$1.56
52 Week High
$3.08
$11.43

Technical Indicators

Market Signals
Indicator
SPRO
RYOJ
Relative Strength Index (RSI) 32.01 36.39
Support Level $1.13 $3.18
Resistance Level $1.29 $4.33
Average True Range (ATR) 0.04 0.54
MACD 0.01 -0.20
Stochastic Oscillator 15.53 0.00

Price Performance

Historical Comparison
SPRO
RYOJ

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About RYOJ rYojbaba Co. Ltd.

rYojbaba Co Ltd is engaged in improving and restoring physical and mental health diminished by work-related stress through consulting and health services. The company provides consulting services to labor unions and companies wishing to build constructive relationships with labor unions and health services to osteopathic clinics and osteopathic beauty salons to alleviate physical ailments created by work-related stress.

Share on Social Networks: